Does personalized medicine cut the mustard when it comes to treating cancer? Richard Smith, a former editor of the British Medical Journal, believes that it does not. Using the mustard metaphor, he shows how personalized medicine undermines the pharmaceutical industry’s profits. If the one-size-fits-all approach to prescribing cancer drugs were abandoned, drug companies would be forced to change their business model, most notably by increasing prices radically – or stop producing the drugs altogether.
View the original article here: Personalized Medicine’s Perverse Economics
Personalized medicine’s perverse economics
Donna Dickenson | Project Syndicate | December 21, 2012
{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
GLP Podcasts & Podcast Videos | More... |
Infographics | More... |
Infographic: Could gut bacteria help us diagnose and treat diseases? This is on the horizon thanks to CRISPR gene editing
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions ...
Most Popular
- Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar?
- Viewpoint: Should you be concerned when you read that a chemical in your food has been linked to cancer? Here’s an epidemiologist’s checklist to detect over-hyped scares
- Viewpoint: Debunking organic food myths again… and again
- Viewpoint: By engineering block on Vitamin A enhanced Golden Rice, Greenpeace ‘puts the whole environmental movement into disrepute’
- How Freddie Mercury got his voice: It wasn’t his teeth
- KFC developing world’s first bioprinted chicken nuggets for planned rollout in Russia in fall 2020
- 25 years of GMO crops: Economic, environmental and human health benefits
- Marrying your cousin? There may be evolutionary benefits
- Viewpoint: The organic food industry is a $180 billion marketing fraud
- AMP v. Myriad Genetics: Do intellectual property protections really stifle innovation?